SynthesisScientific reports2022
Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.
Synthesis in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Formulation of treatment protocol for ocular surface squamous neoplasia.International ophthalmology · 2026Pooled it
- Utility of ultrasound biomicroscopy in detecting invasive ocular surface squamous neoplasia.Indian journal of ophthalmology · 2026Article
- Artificial Intelligence in Ocular Surface Tumors: Current Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- New Paradigm in Ocular Surface Squamous Neoplasia-Insights from a Case Report on the Use of Interferon in Treatment.Oncology research · 2026Article
- High-resolution optical coherence tomography for screening ocular surface tumors: Historical markers and future directions.World journal of clinical cases · 2025Article
- Rapid remission of extensive corneal surface neoplasia with topical interferon therapy.Eye (London, England) · 2025Article
- Detection of Ocular Surface Squamous Neoplasia Using Artificial Intelligence With Anterior Segment Optical Coherence Tomography.American journal of ophthalmology · 2025Article
- Review
- Artificial intelligence to enhance the diagnosis of ocular surface squamous neoplasia.Scientific reports · 2025Article
- IFNα2b/5-FU inhibits proliferation and cell cycle of squamous carcinoma cell line Cal27.International journal of ophthalmology · 2025Article
- Establishment of a nomogram model to predict malignant risk in patients with ocular surface squamous neoplasia and ocular surface squamous epithelial tumors.Frontiers in oncology · 2025Article
- Topical Chemotherapy for Ocular Surface Squamous Neoplasia: A Review of Adverse Effects and Their Clinical Management.Oncology research · 2025Review
- Excision combined with ocular surface reconstruction followed by topical chemotherapy for ocular surface squamous neoplasia.Japanese journal of ophthalmology · 2024Article
- Overcoming Giant Verruca Vulgaris Treatment Obstacles With Siddha Medicine: A Case Report.Cureus · 2024Article
- An unusual presentation of conjunctival squamous cell carcinoma mistaken for a stye.JAAD case reports · 2024Article
- Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.Cancer immunology, immunotherapy : CII · 2023Article
- Revolutionizing ocular cancer management: a narrative review on exploring the potential role of ChatGPT.Frontiers in public health · 2023Review
- Use of Mitomycin C in Ophthalmic Surgery.Journal of current ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular surface squamous neoplasia (OSSN) has different treatment modalities. Although surgical excision has been the gold standard therapeutic option, topical pharmacotherapy agents such as 5-fluorouracil (5-FU), interferon alfa-2b (IFN) and mitomycin-C (MMC) are also commonly used. The protocol was registered (CRD42021224961). Comprehensive literature research was carried out to compare topical pharmacotherapy (5-FU or IFN or MMC) to surgical excision regarding clinical success (tumor resolution), recurrence and complications in patients undergoing treatment for OSSN. From 7859 records, 7 articles were included in the qualitative and 4 in the quantitative synthesis. The outcomes of surgical excision and topical pharmacotherapy were comparable in the included articles. There were no significant differences between surgical excision and topical pharmacotherapy regarding the clinical success [odds ratio (OR): 0.785; confidence interval (CI): 0.130-4.736, P = 0.792)] and tumor recurrence (OR: 0.746; CI: 0.213-2.609; P = 0.646). The most common side effect of the different therapeutic options was dry eye. The highest rate of dry eye symptoms was reported after surgical excision (in 59%). Topical pharmacotherapy with all the 3 agents is as effective and well-tolerable as surgical excision in terms of tumor resolution, recurrence rate and side effects in all OSSN patients suggesting similar long-term clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.